Allergy Therapeutics plc AGY
LSE · Birleşik Krallık · Sağlık Teknolojisi
GBp 4,76+0,01 (+%0,21)
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Ilika (AIM:IKA) says it's now a revenue-generating business, with initial royalties from its Stereax miniature solid-state batteries expected in its 2027 financial year. Releasing its 2026 results, the company said its larger Goliath battery is also attracting interest from defence and e-bike markets, including a collaboration with Brompton Bicycle. Allergy Therapeutics (AIM:AGY) says revenue growth accelerated in its second half, with full-year revenue up 9% to £59.9 million. Double-digit growth is expected next year as Grassmuno enters its first full peak treatment season. Ecora Royalties (L
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million,...
Cordiant Digital Infrastructure (LSE:CORD, FRA:86L) has secured two new customer agreements at its Hudson Interxchange data centre in New York, lifting contracted capacity to around 80% of the floor's saleable space. Billing on the first contract starts in September, with full deployment expected by year-end. Helium One Global Ltd (AIM:HE1, FRA:9K3) says its Colorado joint venture has completed its first helium sale under a short-term offtake agreement after its second commercial helium trailer delivery. With regular exchanges now scheduled, the focus is shifting towards recurring sales and ca
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.